Ellagic acid promotes A549 cell apoptosis via regulating the phosphoinositide 3‑kinase/protein kinase B pathway

Liu,Qiong; Liang,Xiaobing; Niu,Chengwei; Wang,Xuelan

doi:10.3892/etm.2018.6193

Ellagic acid promotes A549 cell apoptosis via regulating the phosphoinositide 3‑kinase/protein kinase B pathway

Authors:
- Qiong Liu
- Xiaobing Liang
- Chengwei Niu
- Xuelan Wang
View Affiliations

Affiliations: Medical Experiment Center, Xinhua College of Sun Yat‑sen University, Guangzhou, Guangdong 510520, P.R. China
Published online on: May 18, 2018 https://doi.org/10.3892/etm.2018.6193
Pages: 347-352

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the anti‑cancer effect of ellagic acid in human non‑small cell lung cancer (NSCLC) A549 cells and to reveal the potential underlying mechanism. The effects of ellagic acid on the cell proliferation of A549 cells were determined by MTT assay. Cell cycle and apoptosis were measured with flow cytometry and Annexin V‑propidium iodide staining. Western blotting was used to measure the expression levels of the phosphatidylinositol 3‑kinase (PI3K)/protein kinas B (Akt) signaling pathway and apoptosis‑associated proteins. It was demonstrated that ellagic acid exerted an inhibitory effect in the proliferation of human NSCLC A549 cells. Flow cytometry demonstrated that G1 phase retention and apoptosis rates were significantly increased after treatment with ellagic acid. Further investigation revealed that ellagic acid treatment diminished the phosphorylation of PI3K and Akt and regulated the expression of apoptosis‑associated proteins in A549 cells. In conclusion, the present results indicated that ellagic acid suppresses cell proliferation, arrests cell cycle and induces apoptosis in human NSCLC A549 cells by inhibiting the PI3K/Akt signaling pathway.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Tieulent Lortet J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S and Agrawal A: Lung cancer biomarkers: State of the art. J Carcinog. 12:32013. View Article : Google Scholar : PubMed/NCBI
3	Zhang L, Huang Y, Zhuo W, Zhu Y, Zhu B and Chen Z: Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways. Am J Transl Res. 8:4857–4868. 2016.PubMed/NCBI
4	Lim SM, Syn NL, Cho BC and Soo RA: Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev. 65:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
5	Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, Yenerall P, Zhou Y, Timmons BC, Rodriguez-Canales J, et al: Taxane-platin-resistant lung cancers Co-develop hypersensitivity to jumonjic demethylase inhibitors. Cell Rep. 19:1669–1684. 2017. View Article : Google Scholar : PubMed/NCBI
6	Chen JH, Lee KY, Hu CJ and Chung CC: Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review. Medicine (Baltimore). 96:e92622017. View Article : Google Scholar : PubMed/NCBI
7	Mocanu MM, Nagy P and Szöllősi J: Chemoprevention of breast cancer by dietary polyphenols. Molecules. 20:22578–22620. 2015. View Article : Google Scholar : PubMed/NCBI
8	Sarkar S, Siddiqui AA, Mazumder S, De R, Saha SJ, Banerjee C, Iqbal MS, Adhikari S, Alam A, Roy S and Bandyopadhyay U: Ellagic acid, a dietary polyphenol inhibits tautomerase activity of human macrophage migration inhibitory factor and its pro-inflammatory responses in human peripheral blood mononuclear cells. J Agr Food Chem. 63:4988–4998. 2015. View Article : Google Scholar
9	Benvenuto M, Fantini M, Masuelli L, De Smaele E, Zazzeroni F, Tresoldi I, Calabrese G, Galvano F, Modesti A and Bei R: Inhibition of ErbB receptors, Hedgehog and NF-kappaB signaling by polyphenols in cancer. Front Biosci (Landmark Ed). 18:1290–1310. 2013. View Article : Google Scholar : PubMed/NCBI
10	Marzocchella L, Fantini M, Benvenuto M, Masuelli L, Tresoldi I, Modesti A and Bei R: Dietary flavonoids: Molecular mechanisms of action as anti-inflammatory agents. Recent Pat Inflamm Allergy Drug Discov. 5:200–220. 2011. View Article : Google Scholar : PubMed/NCBI
11	Talcott ST and Lee JH: Ellagic acid and flavonoid antioxidant content of muscadine wine and juice. J Agr Food Chem. 50:3186–3192. 2002. View Article : Google Scholar
12	Zhao M, Tang SN, Marsh JL, Shankar S and Srivastava RK: Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice. Cancer Lett. 337:210–217. 2013. View Article : Google Scholar : PubMed/NCBI
13	Ceci C, Tentori L, Atzori MG, Lacal PM, Bonanno E, Scimeca M, Cicconi R, Mattei M, de Martino MG, Vespasiani G, et al: Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth. Nutrients. 8:pii: E744. 2016. View Article : Google Scholar : PubMed/NCBI
14	Malik A, Afaq S, Shahid M, Akhtar K and Assiri A: Influence of ellagic acid on prostate cancer cell proliferation: A caspase-dependent pathway. Asian Pac J Trop Med. 4:550–555. 2011. View Article : Google Scholar : PubMed/NCBI
15	Narayanan BA, Geoffroy O, Willingham MC, Re GG and Nixon DW: p53/p21 (WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett. 136:215–221. 1999. View Article : Google Scholar : PubMed/NCBI
16	Ho CC, Huang AC, Yu CS, Lien JC, Wu SH, Huang YP, Huang HY, Kuo JH, Liao WY, Yang JS, et al: Ellagic acid induces apoptosis in TSGH8301 human bladder cancer cells through the endoplasmic reticulum stress-and mitochondria-dependent signaling pathways. Environ Toxicol. 29:1262–1274. 2014.PubMed/NCBI
17	Gul M, Aliosmanoglu I, Uslukaya O, Firat U, Yüksel H, Gümüs M and Ulger BV: The protective effect of ellagic acid on lung damage caused by experimental obstructive jaundice model. Acta Chir Belg. 113:285–289. 2013. View Article : Google Scholar : PubMed/NCBI
18	Favarin Cornelio D, Teixeira Martins M, de Andrade Lemos E, de Freitas Alves C, Chica Lazo JE, Sorgi Artério C, Faccioli LH and Rogerio Paula A: Anti-inflammatory effects of ellagic acid on acute lung injury induced by acid in mice. Mediators Inflamm. 2013:1642022013.PubMed/NCBI
19	Ho CC, Huang AC, Yu CS, Lien JC, Wu SH, Huang YP, Huang HY, Kuo JH, Liao WY, Yang JS, et al: Ellagic acid induces apoptosis in TSGH8301 human bladder cancer cells through the endoplasmic reticulum stress- and mitochondria-dependent signaling pathways. Environ Toxicol. 29:1262–1274. 2014.PubMed/NCBI
20	Morgan TM, Koreckij TD and Corey E: Targeted therapy for advanced prostate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ye G, Lu Q, Zhao W, Du D, Jin L and Liu Y: Fucoxanthin induces apoptosis in human cervical cancer cell line HeLa via PI3K/Akt pathway. Tumor Biol. 35:11261–11267. 2014. View Article : Google Scholar
22	Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, et al: Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): New insights on the role of phosphatydil-inositol-3 kinase. PLoS One. 7:e304272012. View Article : Google Scholar : PubMed/NCBI
23	Xu CX, Jin H, Shin JY, Kim JE and Cho MH: Roles of protein kinase B/Akt in lung cancer. Front Biosci (Elite Ed). 2:1472–1484. 2010.PubMed/NCBI
24	Umesalma S, Nagendraprabhu P and Sudhandiran G: Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells. Mol Cell Biochem. 399:303–13. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W, et al: Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat. 71:203–217. 2002. View Article : Google Scholar : PubMed/NCBI
26	Mitsiades CS, Mitsiades N and Koutsilieris M: The Akt pathway: Molecular targets for anti-cancer drug development. Current Cancer Drug Targets. 4:235–256. 2004. View Article : Google Scholar : PubMed/NCBI
27	Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
28	Saglam O, Garrett CR, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng JQ, Sebti S and Coppola D: Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia. Clinical Colorectal Cancer. 6:652–656. 2007. View Article : Google Scholar : PubMed/NCBI
29	Hanahan D WR: The hallmarks of cancer. Cell. 2000. View Article : Google Scholar